Regulation Change Hurts ViroPharma

Shares of ViroPharma Inc. (VPHM) plunged $5.39 to close at $10.86 after the Food and Drug Administration changed the conditions under which a generic drug applicant may request a waiver for bioequivalency testing for ViroPharma's Vancocin. The decision will bring generic drug products to market sooner.